1. Scrip
  2. >>Focus On Asia
  3. >>India

Glenmark Re-Evaluates Complex Generics Basket, Won’t Be Part Of The 'Crowd'

 
• By Anju Ghangurde

Glenmark has ended development of certain in-licensed complex generic assets including generic versions of Abraxane and Suboxone in view of the extremely competitive landscape in the US. The Indian firm says it would rather focus on products where it is an early entrant.

Pros & Cons
GLENMARK HAS DISCONTINUED DEVELOPMENT OF CERTAIN COMPLEX GENERICS

Competitive pressure in the US market is forcing some Indian companies to rethink their product portfolios including in the complex generics space, once considered a relatively safe haven in terms of both number of participants vying for a share of the pie and intensity of price erosion.

Glenmark Pharmaceuticals Ltd. said it was no longer pursuing development of four in-licensed complex generic assets as the “overall...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from India

More from Focus On Asia

MetaVia Sees Obesity Opportunities Despite Challenging US Market

 
• By Jung Won Shin

Despite new challenges related to obesity drug insurance coverage in the US, MetaVia's CEO is confident in the company's novel contender, which unlike rival GLP-1 therapies doesn’t require dose titration.

Public Health And Innovation: Addressing Gaps, Pharma’s Role

 
• By Anju Ghangurde

Expert panel including Ashok Venkitaraman, director of the Cancer Science Institute of Singapore, discusses public health challenges and innovations to help address these. Long-acting drugs, intercepting cancer early and “design thinking” by ophthalmologists in India were among the talking points.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now